Teduglutide
CAS 197922-42-2 5 FDA-DMF suppliersPeptide
Overview
Teduglutide is a recombinant form of human glucagon-like peptide-2 (GLP-2) that enhances intestinal absorption and is used to treat adults with short bowel syndrome who are dependent upon parenteral support. It increases intestinal and portal blood flow and inhibits gastric acid secretion.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Teduglutide expires 30 Apr 2026 and exclusivity 15 May 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Gastroenterology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.